3 or 6 months adjuvant oxaliplatin for colorectal cancer
4 Jun 2017
3 or 6 months adjuvant oxaliplatin for colorectal cancer
Pooled analysis of avelumab for metastatic urothelial carcinoma
Larotrectinib shows durable efficacy across diverse paediatric and adult cancers
Routine genomic testing is feasible, but only a subset of patients benefit
Molecular profiles and the future of adjuvant therapy
STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths
Editor's Choice for May 2017
EADO conference highlights
Theory and application of electrochemotherapy
Intralesional T-VEC and combinations for melanoma
Molecular testing for targeted therapies
Brain metastases: Gamma knife and new treatments